Gsa Capital Partners LLP Olema Pharmaceuticals, Inc. Transaction History

Gsa Capital Partners LLP

10 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q1 2024 May 03, 2024	SELL	$10.95 - $16.62 $188,635 - $286,312	-17,227 Reduced 38.94%	27,013 $305,000
Q4 2023 Feb 16, 2024	SELL	$10.53 - $17.14 $163,562 - $266,235	-15,533 Reduced 25.99%	44,240 $620,000
Q3 2023 Nov 15, 2023	SELL	$8.19 - $12.98 $344,528 - $546,029	-42,067 Reduced 41.31%	59,773 $738,000
Q2 2023 Aug 14, 2023	SELL	$3.22 - $9.65 $414,710 - $1.24 Million	-128,792 Reduced 55.84%	101,840 $919,000
Q1 2023 May 12, 2023	SELL	$2.55 - $4.97 $2,552 - $4,974	-1,001 Reduced 0.43%	230,632 $800,000
Q4 2022 Feb 13, 2023	BUY	$2.27 - $3.76 $289,536 - $479,584	127,549 Added 122.54%	231,633 $568,000
Q3 2022 Nov 14, 2022	BUY	$2.72 - $5.88 $283,108 - $612,013	104,084 New	104,084 $287,000
Q2 2022 Aug 09, 2022	SELL	$2.04 - $4.61 $147,465 - $333,243	-72,287 Closed	0 $0
Q1 2022 May 11, 2022	BUY	$3.89 - $9.43 $124,713 - $302,325	32,060 Added 79.7%	72,287 $308,000
Q4 2021 Feb 14, 2022	BUY	$8.75 - $30.71 $351,986 - $1.24 Million	40,227 New	40,227 $377,000

136

58.7M

141K

23.1K

Ticker OLMA
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 40,419,600
Market Cap $247M
Description
Olema Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, focuses on the discovery, development, and commercialization of therapies for women's cancers. Its lead product candidate is OP-1250, an estrogen receptor (ER) antagonist and a selective ER degrader, which is in Phase 1/2 clinical trial for the treatment of recurrent, local...

Get notified when there are updates to the investment portfolio of Gsa Capital Partners LLP, based on Form 13F filings with the SEC.

Stay updated on Gsa Capital Partners LLP with notifications on news.